Samuel Ejadi - Concepedia

Author

Samuel Ejadi

Seoul National University Hospital

Also Known As

S. Ejadi, Samuel Ejadi

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Seoul National University Hospital The University of Texas MD Anderson Cancer Center Merck & Co., Inc., Rahway, NJ, USA (United States)Princess Margaret Cancer Centre Mayo Clinic in Arizona

About

Samuel Ejadi is an author at Seoul National University Hospital specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	921
2	Immunology	7	7	697
3	Cell Biology	2	2	54
4	Obstetrics	2	2	120
5	Molecular Medicine	1	1	71

Samuel Ejadi

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad, British Journal of Cancer	2020	850
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi, Journal of Clinical Oncology Keynote-028 StudySolid TumorsImmunologyImmunoeditingCell Death	2017	457
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study Aaron R. Hansen, Christophe Massard, Patrick A. Ott, Annals of Oncology	2018	364
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma Bert H. O’Neil, John M. Wallmark, David Lorente, PLoS ONE	2017	299
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal Patrick A. Ott, Sarina A. Piha‐Paul, Pamela N. Münster, Annals of Oncology	2017	250
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher, Annals of Oncology	2016	229
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. Mary L. Disis, Manish R. Patel, Shubham Pant, Journal of Clinical Oncology ImmunologyProgrammed Death-1 ReceptorGynecologyImmunoeditingImmunotherapeutics	2015	109
Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences Matt Benasutti, Samuel Ejadi, Marc Whitlow, Biochemistry	1988	104
Phase I/II Study of GM-CSF DNA as an Adjuvant for a Multipeptide Cancer Vaccine in Patients With Advanced Melanoma Miguel‐Angel Perales, Jianda Yuan, Sarah Powel, Molecular Therapy	2008	98
Safety and preliminary clinical activity of repotrectinib in patients with advanced <i>ROS1</i> fusion-positive non-small cell lung cancer (TRIDENT-1 study). Byoung Chul Cho, Alexander Drilon, Robert C. Doebele, Journal of Clinical Oncology Trident-1 StudyPathologyTumor BiologyOncologyReceptor Tyrosine Kinase	2019	71

Page 1